Republish
Who benefits from e-cigarette restrictions
We love that you want to share our stories with your readers. Hundreds of publications republish our work on a regular basis.
All of the articles at CalMatters are available to republish for free, under the following conditions:
-
- Give prominent credit to our journalists: Credit our authors at the top of the article and any other byline areas of your publication. In the byline, we prefer “By Author Name, CalMatters.” If you’re republishing guest commentary (example) from CalMatters, in the byline, use “By Author Name, Special for CalMatters.”
-
- Credit CalMatters at the top of the story: At the top of the story’s text, include this copy: “This story was originally published by CalMatters. Sign up for their newsletters.” If you are republishing commentary, include this copy instead: “This commentary was originally published by CalMatters. Sign up for their newsletters.” If you’re republishing in print, omit the second sentence on newsletter signups.
-
- Do not edit the article, including the headline, except to reflect relative changes in time, location and editorial style. For example, “yesterday” can be changed to “last week,” and “Alameda County” to “Alameda County, California” or “here.”
-
- If you add reporting that would help localize the article, include this copy in your story: “Additional reporting by [Your Publication]” and let us know at republish@calmatters.org.
-
- If you wish to translate the article, please contact us for approval at republish@calmatters.org.
-
- Photos and illustrations by CalMatters staff or shown as “for CalMatters” may only be republished alongside the stories in which they originally appeared. For any other uses, please contact us for approval at visuals@calmatters.org.
-
- Photos and illustrations from wire services like the Associated Press, Reuters, iStock are not free to republish.
-
- Do not sell our stories, and do not sell ads specifically against our stories. Feel free, however, to publish it on a page surrounded by ads you’ve already sold.
-
- Sharing a CalMatters story on social media? Please mention @CalMatters. We’re on X, Facebook, Instagram, TikTok and BlueSky.
If you’d like to regularly republish our stories, we have some other options available. Contact us at republish@calmatters.org if you’re interested.
Have other questions or special requests? Or do you have a great story to share about the impact of one of our stories on your audience? We’d love to hear from you. Contact us at republish@calmatters.org.
Who benefits from e-cigarette restrictions
Share this:
In summary
The pharmaceutical industry has shown a hostility to e-cigarettes because they present a direct threat to pharmaceutical products.
Liz Mair, Vapers United, Arlington, Va.
My heart goes out to Sen. Jeff Stone. I have seen family members die painful and drawn-out deaths as a result of smoking-related illnesses. A deep fear of ending up in the same plight is what drove me to quit smoking, via vaping. My personal experiences run counter to what Sen. Stone is suggesting. I no longer smoke or vape or intake nicotine through any non-food means.
I strongly urge Sen. Stone not to discount the experiences of many vapers and former vapers who have proven that vaping can be a pathway to quitting smoking.
Products like Chantix, nicotine gum, and the patch do not work for everyone.
The pharmaceutical industry has shown a hostility to e-cigarettes because, in my opinion, they present a direct threat to pharmaceutical products dominating the market where products that smokers may use to try to quit smoking are concerned.
It is all too easy for anti-vapor advocates to inadvertently wind up doing the bidding of Big Tobacco and Big Pharma, which benefit from vapor crackdowns. Tobacco stock prices went up on the day U.S. Food & Drug Administration Commissioner Scott Gottlieb announced his vapor crackdown last year.
Anyone who is concerned about bringing smoking rates down needs to consider that they may be aiding entities they literally view as the devil incarnate: Principally Big Tobacco, but in the case of some progressives especially, also Big Pharma.